[go: up one dir, main page]

AU2001238485A1 - Methods and compositions for gene delivery - Google Patents

Methods and compositions for gene delivery

Info

Publication number
AU2001238485A1
AU2001238485A1 AU2001238485A AU3848501A AU2001238485A1 AU 2001238485 A1 AU2001238485 A1 AU 2001238485A1 AU 2001238485 A AU2001238485 A AU 2001238485A AU 3848501 A AU3848501 A AU 3848501A AU 2001238485 A1 AU2001238485 A1 AU 2001238485A1
Authority
AU
Australia
Prior art keywords
compositions
methods
gene delivery
gene
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238485A
Inventor
Mariusz Banaszczyk
Alison T. Carlo
Henry C Chiou
Charles Peter Lollo
Patricia M. Mullein
Dongpei Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp filed Critical Immune Response Corp
Publication of AU2001238485A1 publication Critical patent/AU2001238485A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001238485A 2000-02-18 2001-02-16 Methods and compositions for gene delivery Abandoned AU2001238485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18351600P 2000-02-18 2000-02-18
US60183516 2000-02-18
PCT/US2001/005234 WO2001060415A1 (en) 2000-02-18 2001-02-16 Methods and compositions for gene delivery

Publications (1)

Publication Number Publication Date
AU2001238485A1 true AU2001238485A1 (en) 2001-08-27

Family

ID=22673132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238485A Abandoned AU2001238485A1 (en) 2000-02-18 2001-02-16 Methods and compositions for gene delivery

Country Status (2)

Country Link
AU (1) AU2001238485A1 (en)
WO (1) WO2001060415A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835749B1 (en) 2002-02-08 2006-04-14 Inst Nat Sante Rech Med PHARMACEUTICAL COMPOSITION IMPROVING IN VIVO GENE TRANSFER
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic agent using protein hollow nanoparticles that display growth factors etc.
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Drug for treating liver disease using hollow protein nanoparticles
EP1594962B1 (en) * 2003-01-31 2014-08-27 Promega Corporation Covalent tethering of functional groups to proteins
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
EP3179252B1 (en) * 2004-07-30 2018-11-14 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
CA2667697A1 (en) 2006-10-30 2008-05-08 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and functional expression
GB0816783D0 (en) 2008-09-15 2008-10-22 Carmeda Ab Immobilised biological entities
KR101020050B1 (en) * 2008-10-06 2011-03-09 포항공과대학교 산학협력단 Gene delivery system using linear polyethyleneimine-branched polyethyleneglycol compound and its synthesis method
RU2582235C2 (en) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Low-molecular conjugates for intracellular delivery of nucleic acids
EP2727911B1 (en) * 2012-10-31 2016-12-21 Medizinische Hochschule Hannover Novel means and methods for treating malaria and other parasitic disorders
WO2015078995A1 (en) * 2013-11-28 2015-06-04 Institut National de la Santé et de la Recherche Médicale Agents for treating cystic fibrosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719316B1 (en) * 1994-04-28 1996-05-31 Idm New nucleic acid and polymer complexes, their preparation process and their use for cell transfection.
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
AU1820999A (en) * 1997-12-12 1999-06-28 Expression Genetics, Inc. Grafted copolymers as gene carriers

Also Published As

Publication number Publication date
WO2001060415A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2625501A (en) Compositions and methods for gene silencing
AU2001280968A1 (en) Compositions and methods for directed gene assembly
AU2778801A (en) Antisense compositions and methods
AU9692198A (en) Gene delivery compositions and methods
AU2002357119A1 (en) Mitocidal compositions and methods
AU2001271720A1 (en) Methods and compositions for determining gene function
GB0012997D0 (en) Gene delivery
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001232020A1 (en) Floating drug delivery composition
MXPA02003232A (en) Compositions and methods for altering gene expression.
AU2001238485A1 (en) Methods and compositions for gene delivery
AU2001288395A1 (en) Method for enhanced delivery of oxybutynin and compositions thereof
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2002365188A1 (en) Nucleic acid delivery and expression
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
AU2001242625A1 (en) Gene sequence
AU2002306461A1 (en) In vivo delivery methods and compositions
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2001297738A1 (en) Gene delivery device and gene delivery method
AU2001264247A1 (en) GASC1 gene
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU5474400A (en) Compositions and methods for targeted gene insertion